0001610717-24-000490.txt : 20240919 0001610717-24-000490.hdr.sgml : 20240919 20240919163550 ACCESSION NUMBER: 0001610717-24-000490 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240917 FILED AS OF DATE: 20240919 DATE AS OF CHANGE: 20240919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lenz Robert A. CENTRAL INDEX KEY: 0001992908 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41802 FILM NUMBER: 241310826 MAIL ADDRESS: STREET 1: C/O NEUMORA THERAPEUTICS, INC. STREET 2: 490 ARSENAL WAY, SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neumora Therapeutics, Inc. CENTRAL INDEX KEY: 0001885522 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 844367680 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY, SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (857) 760-0900 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY, SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: RBNC Therapeutics, Inc. DATE OF NAME CHANGE: 20210929 4 1 form4.xml X0508 4 2024-09-17 0001885522 Neumora Therapeutics, Inc. NMRA 0001992908 Lenz Robert A. C/O NEUMORA THERAPEUTICS, INC. 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 true Head of R&D true Common Stock 2024-09-17 4 S 0 30788 11.8142 D 339205 D Common Stock 2024-09-18 4 S 0 10676 12.0917 D 328529 D The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024. This transaction was executed in multiple trades in prices ranging from $11.5985 to $12.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $12.00 to $12.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. /s/ Joshua Pinto, as Attorney-in-Fact for Robert A. Lenz 2024-09-19